Related references
Note: Only part of the references are listed.Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial
Ian F. Tannock et al.
LANCET ONCOLOGY (2013)
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer
Jatinder Goyal et al.
BJU INTERNATIONAL (2012)
The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
Saroj Niraula et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
Srikala S. Sridhar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
From Efficacy to Effectiveness in the Face of Uncertainty Indication Creep and Prevention Creep
Benjamin Djulbegovic et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials
Bostjan Seruga et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
SYNERGY: A randomized phase III study comparing firstline docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC).
K. N. Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
Kim N. Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
What Constitutes Reasonable Evidence of Efficacy and Effectiveness to Guide Oncology Treatment Decisions?
Daniel Sargent
ONCOLOGIST (2010)
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: Relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study
Dominik R. Berthold et al.
CLINICAL CANCER RESEARCH (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy vs. effectiveness — docetaxel and prednisone in hormone refractory prostate cancer
Diana N Howard et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2008)
Comparison of outcomes in cancer patients treated within and outside clinical trials: Conceptual framework and structured review
JM Peppercorn et al.
LANCET (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
